LLY

1,000.32

+1.04%↑

JNJ

226.86

+0.95%↑

ABBV

205.07

-1.3%↓

UNH

401.47

+4.08%↑

AZN

184.66

+0.27%↑

LLY

1,000.32

+1.04%↑

JNJ

226.86

+0.95%↑

ABBV

205.07

-1.3%↓

UNH

401.47

+4.08%↑

AZN

184.66

+0.27%↑

LLY

1,000.32

+1.04%↑

JNJ

226.86

+0.95%↑

ABBV

205.07

-1.3%↓

UNH

401.47

+4.08%↑

AZN

184.66

+0.27%↑

LLY

1,000.32

+1.04%↑

JNJ

226.86

+0.95%↑

ABBV

205.07

-1.3%↓

UNH

401.47

+4.08%↑

AZN

184.66

+0.27%↑

LLY

1,000.32

+1.04%↑

JNJ

226.86

+0.95%↑

ABBV

205.07

-1.3%↓

UNH

401.47

+4.08%↑

AZN

184.66

+0.27%↑

Home・Aandelen Lijst・Kura Oncology Inc
Search

Kura Oncology Inc

Open

SectorGezondheidszorg

9.19 -4.37

Strong Buy

Prijsupdate 13 mei 2026, 15:26 UTC

BuySell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

8.72

Max

9.93

Belangrijke statistieken

By Trading Economics

Inkomsten

-6.9M

-81M

Verkoop

-3.4M

17M

Winstmarge

-467.23

Werknemers

260

EBITDA

-12M

-86M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+195.79% upside

Dividenden

By Dow Jones

Volgende Winsten

6 aug 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

89M

844M

Vorige openingsprijs

13.56

Vorige sluitingsprijs

9.19

Nieuwssentiment

By Acuity

77%

23%

320 / 346 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

5.575 / 6.6 Steun & Weerstand

Kura Oncology Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

12 mei 2026, 22:50 UTC

Winsten

Commonwealth Bank of Australia Increases Provisions as 3Q Profit Slips

DJ

Lezen

12 mei 2026, 22:49 UTC

Winsten

Aristocrat Leisure Raises Midyear Dividend, Swells Share Buyback Program

DJ

Lezen

12 mei 2026, 22:32 UTC

Winsten

JBS 1Q Profit Slides Amid Rising Cattle Costs -- Update

DJ

Lezen

12 mei 2026, 23:48 UTC

Marktinformatie

Nikkei May Decline Amid Uncertainty Over Iran Conflict -- Market Talk

DJ

Lezen

12 mei 2026, 22:57 UTC

Marktinformatie
Winsten

JBS Says Consumers Are Looking to Pork for Affordable Protein -- Market Talk

DJ

Lezen

12 mei 2026, 22:26 UTC

Winsten

Aristocrat Leisure to Increase On-Market Share Buyback by A$1 Billion

DJ

Lezen

12 mei 2026, 22:25 UTC

Winsten

Aristocrat Leisure 1H Normalized Pretax Profit A$997.3 Million, Up 9.4% on Year

DJ

Lezen

12 mei 2026, 22:25 UTC

Winsten

Aristocrat Leisure Interim Dividend A$0.50/Security

DJ

Lezen

12 mei 2026, 22:24 UTC

Winsten

Aristocrat Leisure 1H Revenue From Continuing Operations A$3.03 Billion, Down 0.2% on Year

DJ

Lezen

12 mei 2026, 22:23 UTC

Winsten

Aristocrat Leisure 1H Net Profit From Discontinued Operations A$7.0 Million

DJ

Lezen

12 mei 2026, 22:23 UTC

Winsten

Aristocrat Leisure 1H Net Profit From Continuing Operations A$798.5 Million, Up 56%

DJ

Lezen

12 mei 2026, 22:19 UTC

Winsten

CBA: Total Provision Coverage Ratio 1.57%>CBA.AU

DJ

Lezen

12 mei 2026, 22:14 UTC

Winsten

CBA: Business Lending Continued to Grow Above System>CBA.AU

DJ

Lezen

12 mei 2026, 22:14 UTC

Winsten

CBA Had 1.4M Business Transaction Accounts at March 31, Up 7% on Year>CBA.AU

DJ

Lezen

12 mei 2026, 22:13 UTC

Winsten

CBA Household Deposits Grew A$38B in 12 Months Through March>CBA.AU

DJ

Lezen

12 mei 2026, 22:12 UTC

Winsten

CBA Home Loan Balances Grew A$41B in 12 Months Through March>CBA.AU

DJ

Lezen

12 mei 2026, 22:12 UTC

Winsten

CBA 3Q New Home Loan Funding A$45B>CBA.AU

DJ

Lezen

12 mei 2026, 22:11 UTC

Winsten

Correct: JBS NV 1Q EPS 20c, Not 21c >JBS

DJ

Lezen

12 mei 2026, 22:11 UTC

Winsten

CBA: CET1 Level 2 Capital Ratio 11.6%>CBA.AU

DJ

Lezen

12 mei 2026, 22:10 UTC

Winsten

CBA: Customer Deposit Funding Ratio 79%>CBA.AU

DJ

Lezen

12 mei 2026, 22:09 UTC

Winsten

CBA: Underlying Portfolio Credit Quality Remains Sound>CBA.AU

DJ

Lezen

12 mei 2026, 22:09 UTC

Winsten

CBA: Higher Collective Provisions Reflect Geopolitical, Macroeconomic Uncertainty >CBA.AU

DJ

Lezen

12 mei 2026, 22:08 UTC

Winsten

CBA 3Q Loan Impairment Expense A$316M>CBA.AU

DJ

Lezen

12 mei 2026, 22:07 UTC

Winsten

CBA: Costs Up on Higher Cloud Computing Volumes, Software Licenses, AI Investment>CBA.AU

DJ

Lezen

12 mei 2026, 22:06 UTC

Winsten

CBA 3Q Operating Expenses Up 1% Excluding Restructuring, Notable Items>CBA.AU

DJ

Lezen

12 mei 2026, 22:06 UTC

Winsten

CBA: 3Q Underlying Net Interest Margin Was Broadly Stable>CBA.AU

DJ

Lezen

12 mei 2026, 22:05 UTC

Winsten

CBA: Lending, Deposit Volume Growth Offset Impact of Two Fewer Days >CBA.AU

DJ

Lezen

12 mei 2026, 22:04 UTC

Winsten

Commonwealth Bank: Operating Income Flat in March Quarter >CBA.AU

DJ

Lezen

12 mei 2026, 22:04 UTC

Winsten

Commonwealth Bank 3Q Cash Profit Up 4% on Year>CBA.AU

DJ

Lezen

12 mei 2026, 22:04 UTC

Winsten

Commonwealth Bank 3Q Cash Profit Down 1% on 1H Quarterly Average>CBA.AU

DJ

Lezen

Peer Vergelijking

Prijswijziging

Kura Oncology Inc Prognose

Koersdoel

By TipRanks

195.79% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 28.13 USD  195.79%

Hoogste 40 USD

Laagste 15 USD

Gebaseerd op 10 Wall Street-analisten die 12-maands prijsdoelen bieden voor Kura Oncology Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

10 ratings

9

Buy

1

Hold

0

Sell

Gebaseerd op 10 analisten die aandelenratings hebben gegeven aan Kura Oncology Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

5.575 / 6.6Steun & Weerstand

Korte Termijn

Very Strong Bearish Evidence

Recent bearish events outweigh bullish events.

Gemiddeld Termijn

Strong Bullish Evidence

Recent bullish events outweigh bearish events.

Lange Termijn

Bearish Evidence

All events are bearish.

Sentiment

By Acuity

320 / 346 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.

Andere aandelen uit de sector

LLY

Eli Lilly and Co.

1,000.32

↑ +1.04%

JNJ

Johnson and Johnson

226.86

↑ +0.95%

ABBV

AbbVie Inc

205.07

↓-1.3%

UNH

UnitedHealth Group Inc

401.47

↑ +4.08%

AZN

AstraZeneca PLC

184.66

↑ +0.27%
help-icon Live chat